CROI 2015 Program and Abstracts

Oral Sessions

WEDNESDAY, FEBRUARY 25, 2015

85LB Levonorgestrel Implant + EFV-Based ART: Unintended Pregnancies and Associated PK Data Kimberly K. Scarsi 1 ; Kristin M. Darin 3 ; Shadia Nakalema 2 ; David Back 4 ; Pauline Byakika- Kibwika 2 ; Laura Else 4 ; Sujan Dilly-Penchala 4 ; Susan Cohn 3 ; Concepta Merry 5 ; Mohammed Lamorde 2 1 University of Nebraska Medical Center, Omaha, NE, US; 2 Infectious Diseases Institute, Kampala, Uganda; 3 Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 4 University of Liverpool, Liverpool, United Kingdom; 5 Trinity College Dublin, Dublin, Ireland 86LB A Phase IV PrEP Study Reveals Limited Ex Vivo Potency of Oral Maraviroc Against HIV-1 Julie Fox 1 ; Carolina Herrera 2 ; Juan ManuelTiraboschi 1 ; Akil Jackson 3 ; Laura Else 4 ; Natalia Olejniczak 2 ; Saye Khoo 4 ; David Back 4 ; Robin Shattock 2 ; Marta Boffito 3 On behalf of KCL Infectious Diseases Biobank 1 Guys and St Thomas’ NHS Foundation Trust, London, United Kingdom; 2 Imperial College London, London, United Kingdom; 3 Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; 4 University of Liverpool, Liverpool, United Kingdom 10:00 am– 12:15 pm KS and Cervical/Anal Dysplasia: Tale of 2 Tumors, and TB and Other OIs Moderators Corey Casper , Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US Timothy Sterling , Vanderbilt University, Nashville, TN, US 87 Pomalidomide for Kaposi Sarcoma in PeopleWith andWithout HIV: A Phase I/II Study Mark N. Polizzotto 1 ;Thomas S. Uldrick 1 ; Kathleen M.Wyvill 1 ; Karen Aleman 1 ; Margaret Bevans 2 ; Cody Peer 1 ; Douglas Figg 1 ; Seth Steinberg 1 ; Jerome B. Zeldis 5 ; RobertYarchoan 1 1 National Cancer Institute (NCI), Bethesda, MD, US; 2 National Institutes of Health (NIH), Bethesda, MD, US; 3 National Cancer Institute (NCI), Bethesda, MD, US; 4 National Cancer Institute (NCI), Bethesda, MD, US; 5 Celgene Corporation, Summit, NJ, US 88 Prognostic Model for Patients With Kaposi Sarcoma TreatedWith ART Alone in Africa Miriam O. Laker-Oketta 1 ; DavidV. Glidden 2 ;VictoriaWalusansa 1 ; Jackson Orem 1 ; A. Rain Mocello 2 ;Toby Maurer 2 ; PeterW. Hunt 2 ; Andrew D. Kambugu 1 ; Edward Mbidde 1 ; Jeffrey Martin 2 1 Makerere University College of Health Sciences, Kampala, Uganda; 2 University of California San Francisco, San Francisco, CA, US; 3 Makerere University College of Health Sciences, Kampala, Uganda; 4 University of California San Francisco (UCSF), San Francisco, CA, US; 5 University of California San Francisco (UCSF), San Francisco, CA, US 89 One-Year Follow-up of HIV+Women ScreenedWith VIA, Cytology and HPV in South Africa Cynthia Firnhaber 1 ; Bridgette Goeieman 1 ; Lu Mao 2 ; Mark Faesen 3 ; Simon Levin 3 ; Sophie Williams 3 ; Avril Swarts 1 ; PamMichelow 1 ;Tanvier Omar 1 ; Jennifer Smith 2 1 University of Witswatersrand, Johannesburg, South Africa; 2 University of North Carolina, Raleigh, NC, US; 3 Right to Care, Johannesburg, South Africa 90 High Rate of HSIL on HRA in HIV+Women Not Meeting Criteria for Anal Cancer Screening Michael M. Gaisa; Fanny Ita-Nagy ; Gabriela Rodriguez Caprio; Michael Mullen; Judith Aberg; Michelle Cespedes Icahn School of Medicine at Mount Sinai, New York, NY, US 91 Xpert MTB/RIF Ultra: A New Near-Patient TB Test With Sensitivity Equal to Culture Session O-7 Oral Abstracts Room 613

Session PL-1 Plenary

4AB Auditorium

8:30 am– 9:00 am Preventing Pediatric HIV and Managing HIV-Infected Children: Where AreWe Now andWhere AreWe Going? 78 Preventing Pediatric HIV and Managing HIV-Infected Children: Where AreWe Now, andWhere AreWe Going? Diana M. Gibb University College London, London, United Kingdom Session PL-2 Plenary 4AB Auditorium 9:00 am– 9:30 am Directing Chronic Virus Infection Through Viral Regulation of Innate Immune Defenses 79 Directing Chronic Virus Infection Through Viral Regulation of Innate Immune Defenses Michael Gale University of Washington, Center for Innate Immunity and Immune Disease, Seattle, WA, US Session O-6 Scientific Overview and Oral Abstracts Room 615 10:00 am– 12:00 pm Intracellular and Clinical Pharmacology, Drug Interactions, and Adherence Moderators Reina Bendayan , University of Toronto, Toronto, ON, Canada Marta Boffito , Chelsea and Westminster Hospital, NHS Foundation Trust/Imperial College, London, United Kingdom 80 Scientific Overview: The Clinical Pharmacology of HIV Prevention Marta Boffito Chelsea and Westminster Hospital, NHS Foundation Trust/Imperial College, London, United Kingdom 81 Intracellular Pharmacokinetics of Sofosbuvir In Vivo Joseph Rower 1 ; Ariel Hodara 1 ; Jacob A. Langness 3 ; SarahTise 1 ; Greg Everson 1 ; Aimee Truesdale 2 ; Fafa Baouchi-Mokrane 2 ; Lane Bushman 1 ; Peter L. Anderson 1 ; Jennifer J. Kiser 1 1 University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, US; 2 Denver Health and Hospital Authority, Denver, CO, US; 3 University of Colorado Health, Aurora, CO, US; 4 University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, US 82 Drug-Drug Interactions Between Anti-HCV Regimen Ledipasvir/ Sofosbuvir and Antiretrovirals Polina German ; Kimberly Garrison; Phillip S. Pang; Luisa M. Stamm; Adrian S. Ray; Gong Shen; Marc Buacharern; Anita Mathias Gilead Sciences, Inc., Foster City, CA, US 83 Emtricitabine-Triphosphate in Dried Blood Spots (DBS) as a Marker of Recent Dosing Jose R. Castillo-Mancilla 1 ; Lane R. Bushman 1 ; Amie Meditz 2 ; Sharon M. Seifert 1 ; Jia-Hua Zheng 1 ; L Anthony Guida 1 ; Edward M. Gardner 3 ; DavidV. Glidden 4 ; Robert M. Grant 4 ; Peter L. Anderson 1 1 University of Colorado-AMC, Aurora, CO, US; 2 Beacon Center for Infectious Diseases, Boulder, CO, US; 3 Denver Health and Hospital Authority, Denver, CO, US; 4 University of California San Francisco, San Francisco, CA, US 84 Impact of EFV PK/PG on Neuropsychological Performance in Older HIV+ Patients Uriel S. Sandkovsky 1 ; AnthonyT. Podany 1 ; Courtney Fletcher 1 ; Andrew Owen 2 ; Angela Felton-Coleman 1 ; Kevin Robertson 3 ; Susan Swindells 1 1 University of Nebraska Medical Center, Omaha, NE, US; 2 University of Liverpool, Liverpool, United Kingdom; 3 University of North Carolina, Chapel Hill, NC, US

Wednesday, February 25, 2015 • Oral Sessions

David Alland 1 ; Mazhgan Rowneki 1 ; Laura Smith 1 ; Jamie Ryan 2 ; Mitchell Chancellor 2 ; Ann Marie Simmons 2 ; David Persing 2 ; Robert Kwiatkowski 2 ; Martin Jones 2 ; Soumitesh Chakravorty 1 1 Rutgers New Jersey Medical School, Newark, NJ, US; 2 Cepheid, Sunnyvale, CA, US

10

CROI 2015